lorvotuzumab mertansine lorvotuzumab mertansine lorvotuzumab mertansine (imgn901) is an antibody-drug conjugate. it comprises the cd56-binding antibody, lorvotuzumab (hun901), with a maytansinoid cell-killing agent, dm1, attached using a disulfide linker, spp. (when dm1 is attached to an antibody with the spp linker, it is mertansine; when it is attached with the thioether linker, smcc, it is emtansine.) lorvotuzumab mertansinemonoclonal antibodytypewhole antibodysourcehumanizedtargetcd56clinical dataatc codenoneidentifierscas number1008106-64-6 nchemspidernoneunii0ivd6asy0wkeggd09927 n ny (what is this?) (verify) lorvotuzumab mertansine is an experimental agent created for the treatment of cd56 positive cancers (e.g. small-cell lung cancer, ovarian cancer). it has been granted orphan drug status for merkel cell carcinoma. it has reported encouraging phase ii results for small-cell lung cancer.